← Metformin × all-cause mortality

SynthesisThe Annals of pharmacotherapy2023

Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Kegang Zhan et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with fewer deaths

−34%−42% to −25%

Bigger than 8 in 10 for all-cause mortality

As reported

OR 0.66, 95% CI 0.58–0.75 · the paper's word: All-cause mortality

Correlation, not cause

Went with fewer deaths

−20%−27% to −12%

Bigger than 6 in 10 for all-cause mortality

As reported

OR 0.80, 95% CI 0.73–0.88 · the paper's word: All-cause mortality

Correlation, not cause

Went with fewer deaths

−17%−30% to −2%

Bigger than 5 in 10 for all-cause mortality

As reported

OR 0.83, 95% CI 0.70–0.98 · the paper's word: All-cause mortality

+2 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

We found that the use of metformin (OR = 0.66, 95% CI: 0.58-0.75), SGLT-2i (OR = 0.80, 95% CI: 0.73-0.88), and GLP-1ra (OR = 0.83, 95% CI: 0.70-0.98) were significantly associated with lower mortality risk in COVID-19 patients with T2D, while insulin use might unexpectedly increase the ICU admission rate (OR = 2.32, 95% CI: 1.34-4.01) and risk of death (OR = 1.52, 95% CI: 1.32-1.75).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
OR 0.660.58–0.75
All-cause mortality
OR 0.800.73–0.88
All-cause mortality
OR 0.830.70–0.98
All-cause mortality
OR 2.321.34–4.01
All-cause mortality
OR 1.521.32–1.75
MetforminAll-cause mortality
1 / 3

7 papers cite it

2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 36314281